# Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study

> **NCT02219165** · PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 30 (actual)

## Conditions studied

- Toxic Shock Syndrome

## Interventions

- **DRUG:** Intravenous human immunoglobulin
- **DRUG:** Albumin

## Key facts

- **NCT ID:** NCT02219165
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-08
- **Primary completion:** 2019-04-19
- **Final completion:** 2019-04-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219165, "Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02219165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*